Publicaciones (71) Publicaciones de MARTA MARIA VARELA REY

2024

  1. Neddylation orchestrates the complex transcriptional and posttranscriptional program that drives Schwann cell myelination

    Science Advances, Vol. 10, Núm. 15

  2. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

    Hepatology, Vol. 77, Núm. 5, pp. 1654-1669

  2. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  3. Hepatic p63 regulates glucose metabolism by repressing SIRT1

    Gut, Vol. 72, Núm. 3, pp. 472-483

  4. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

    Molecular Metabolism, Vol. 75

  5. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models

    Advanced Drug Delivery Reviews, Vol. 181

  2. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24

  3. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 15-28

  4. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

    Nature Communications, Vol. 13, Núm. 1

  5. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals

    Hepatology, Vol. 75, Núm. 3, pp. 550-566

2021

  1. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury

    JHEP Reports, Vol. 3, Núm. 3

  2. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  3. Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 34-45

  4. O-GlcNAcylated p53 in the liver modulates hepatic glucose production

    Nature Communications, Vol. 12, Núm. 1

  5. The L-α-Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis

    Hepatology, Vol. 73, Núm. 2, pp. 606-624

2020

  1. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

    The Journal of clinical investigation, Vol. 130, Núm. 7, pp. 3848-3864

  2. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

    Nature Communications, Vol. 11, Núm. 1

  3. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

    Cell Metabolism, Vol. 31, Núm. 3, pp. 605-622.e10